Skip to content
Pharma Observatory a Scientist.com platform

Organization (Industry)

Abbott Medical Optics

ClinicalTrials.gov lists Abbott Medical Optics as lead sponsor of 35 trials. It has 7 active development programs.

US Industry Manufacturer
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

9 0 1999 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 2 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 2 in 2026 and about 4 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 2 already registered with a 2026 start date: at the cutoff, 1 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.

Logo Johnson & Johnson Services, Inc., via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.

This page covers Abbott Medical Optics: 35 lead-sponsored trials and 0 legal-entity registrations.

Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.

Get the Abbott Medical Optics report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (12)

Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).

Disease areas
Disease area Trials
Cataract 55
Astigmatism 15
Myopia 7
Presbyopia 5
Glaucoma 3

Trials by start year as sponsor or collaborator (24)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 2
2025 4
2024 4
2023 3
2022 9
2021 8
2020 5
2019 4
2018 6
2017 3

Recruitment duration, a model prediction: none of the 71 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (7)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Systane Xerophthalmia Phase 2 1
(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400 Xerophthalmia Phase 2 1
(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400 Dry Eye Syndromes Phase 2 1
Systane Dry Eye Syndromes Phase 2 1
Intervention Cataract Not reported 4

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
12% hit target (n=33) 33% on time (n=33)

FDA inspection record (1)

FDA inspection record
Latest classification Inspections
NAI 9

FDA recalls (45)

Shown in this order: most recent first.

FDA recalls
Product Classification Initiated
Johnson & Johnson VISION Reusable LAMINAR High Flow Irrigation Sleeve and Test Chamber 21 Gauge REF OPOHF21L The irrigation sleeve is a device intended to direct irrigation solution across the shaft of a phacoemulsification tip, allowing the solution to enter the eye during ocular surgery. Class II 2024-03-14
TECNIS Toric II OptiBlue IOL Models ZCW Class II 2023-12-12
TECNIS Symfony, Extended Range of Vision IOL, REF: ZXR00, STERILE.EO, Rx Only Class II 2023-07-06
TECNIS Eyhance IOL, REF: ICB00, STERILE.EO, Rx Only Class II 2023-07-06
VERITAS Advanced Infusion Packs (VRT-AI) and VERITAS Advanced Fluidics Packs (VRT-AF) Class II 2023-05-30

FDA import refusals (1)

FDA import refusals
Refused import lines Latest refusal
4 2024-10-08

Manufacturing and distribution sites (1)

Manufacturing and distribution sites
Facility Location Regulators Member organization
Johnson & Johnson Surgical Vision, Inc. Irvine, US FDA

CLIA clinical laboratory certificates (1)

CLIA clinical laboratory certificates
Lab Certificate Status
JOHNSON & JOHNSON SURGICAL VISION Certificate of waiver Terminated

Biomarker capability evidence (23)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
GUCY2C Trial sponsor Named in trial inclusion criteria
GUCY2C Trial sponsor Named in trial inclusion criteria
KRT7 Trial sponsor Named in trial inclusion criteria
SCLY Trial sponsor Named in trial inclusion criteria
STAR Trial sponsor Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, climate targets, as filed, workforce and board diversity, as filed, and organization relationships.

Counted at group level under Johnson & Johnson: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.